Chlorothiazide - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (4)Transporters (1)

Targets (4)Transporters (1)Biointeractions (5)

Identification

Name

Chlorothiazide

Accession Number

DB00880 (APRD00721)

Type

Small Molecule

Groups

Approved, Vet Approved

Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide

6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide

Chlorothiazid

Chlorothiazide

Chlorothiazidum

Chlorthiazide

Clorotiazida

Mechlozid

Uroflux

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Chlorothiazide Sodium	SN86FG7N2K	7085-44-1	CPIWHAFLBZQYLQ-UHFFFAOYSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Chlorothiazide Sodium	Injection	500 mg/1	Intravenous	Akorn	2012-08-13	Not applicable	US
Diuril	Suspension	250 mg/5mL	Oral	Salix Pharmaceuticals	1962-02-15	Not applicable	US
Sodium Diuril	Injection	.5 mg/18mL	Intravenous	Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)	1958-10-03	Not applicable	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Chlorothiazide	Tablet	250 mg/1	Oral	West Ward Pharmaceutical	2005-08-30	Not applicable	US
Chlorothiazide	Injection, powder, lyophilized, for solution	500 mg/18mL	Intravenous	Fresenius Kabi	2009-10-21	Not applicable	US
Chlorothiazide	Tablet	500 mg/1	Oral	Mylan Pharmaceuticals	1975-07-17	Not applicable	US
Chlorothiazide	Tablet	250 mg/1	Oral	Golden State Medical Supply	2005-08-30	Not applicable	US
Chlorothiazide	Tablet	500 mg/1	Oral	West Ward Pharmaceutical	2005-08-30	Not applicable	US
Chlorothiazide	Tablet	250 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-01	Not applicable	US
Chlorothiazide	Tablet	500 mg/1	Oral	Golden State Medical Supply	2005-08-30	Not applicable	US
Chlorothiazide	Tablet	250 mg/1	Oral	Mylan Pharmaceuticals	1975-06-26	Not applicable	US
Chlorothiazide Sodium	Injection, powder, lyophilized, for solution	500 mg/18mL	Intravenous	Mylan Institutional	2014-08-08	Not applicable	US
Chlorothiazide Sodium	Injection, powder, lyophilized, for solution	500 mg/18mL	Intravenous	Sagent Pharmaceuticals	2015-10-12	Not applicable	US
Chlorothiazide Sodium	Injection, powder, lyophilized, for solution	500 mg/18mL	Intravenous	American Regent	2015-04-01	Not applicable	US
Chlorothiazide Sodium	Injection, powder, lyophilized, for solution	500 mg/18mL	Intravenous	Sun Pharma Global FZE	2011-08-05	2017-02-07	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Supres 150 Tab	Chlorothiazide Methyldopa	Tablet	Oral	Merck Frosst Canada & Cie, Merck Frosst Canada & Co.	1972-12-31	2000-06-14	Canada
Supres 250 Tab	Chlorothiazide Methyldopa	Tablet	Oral	Merck Frosst Canada & Cie, Merck Frosst Canada & Co.	1972-12-31	2000-06-14	Canada

Categories

UNII

77W477J15H

CAS number

58-94-6

Weight

Average: 295.723
Monoisotopic: 294.948824782

Chemical Formula

C₇H₆ClN₃O₄S₂

InChI Key

JBMKAUGHUNFTOL-UHFFFAOYSA-N

InChI

InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)

IUPAC Name

6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide

SMILES

NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1

Pharmacology

Indication

Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Structured Indications

Pharmacodynamics

Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na⁺/Cl^- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Mechanism of action

As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Solute carrier family 12 member 3	Protein	yes	inhibitor	Human	P55017	details
Carbonic anhydrase 1	Protein	yes	inhibitor	Human	P00915	details
Carbonic anhydrase 2	Protein	yes	inhibitor	Human	P00918	details
Carbonic anhydrase 4	Protein	yes	inhibitor	Human	P22748	details

Absorption

Rapidly absorbed following oral administration.

Volume of distribution

Not Available

Protein binding

Approximately 40% bound to plasma proteins.

Metabolism

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney.

Route of elimination

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney. After oral doses, 10 to 15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Half life

45-120 minutes

Clearance

Not Available

Toxicity

Oral, rat LD₅₀: > 10 g/kg. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Chlorothiazide Action Pathway	Drug action	SMP00078

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorothiazide.	Investigational
19-norandrostenedione	19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Chlorothiazide.	Investigational
5-androstenedione	5-androstenedione may increase the hypokalemic activities of Chlorothiazide.	Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Chlorothiazide.	Experimental
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Acebutolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acebutolol.	Approved
Aceclofenac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetazolamide.	Approved, Vet Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide.	Withdrawn
Acetyldigitoxin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.	Approved
Acetylsalicylic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid.	Approved, Vet Approved
Aclidinium	The serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.	Approved
Adapalene	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene.	Approved
AICA ribonucleotide	The therapeutic efficacy of Aicar can be decreased when used in combination with Chlorothiazide.	Experimental
Alclometasone	Alclometasone may increase the hypokalemic activities of Chlorothiazide.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.	Approved
Aldosterone	Aldosterone may increase the hypokalemic activities of Chlorothiazide.	Experimental
Alfacalcidol	Chlorothiazide may increase the hypercalcemic activities of Alfacalcidol.	Approved, Nutraceutical
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorothiazide.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Aliskiren.	Approved, Investigational
Allopurinol	The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorothiazide.	Approved
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorothiazide.	Experimental, Illicit
Alprenolol	Alprenolol may increase the hypotensive activities of Chlorothiazide.	Approved, Withdrawn
Ambrisentan	Chlorothiazide may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amcinonide	Amcinonide may increase the hypokalemic activities of Chlorothiazide.	Approved
Amifostine	Chlorothiazide may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Chlorothiazide.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amiodarone.	Approved, Investigational
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Chlorothiazide.	Approved
Amobarbital	Amobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amphotericin B.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amyl Nitrite.	Approved
Andrographolide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with HMPL-004.	Investigational
Androstenedione	4-Androstenedione may increase the hypokalemic activities of Chlorothiazide.	Experimental, Illicit
Anecortave	Anecortave may increase the hypokalemic activities of Chlorothiazide.	Investigational
Anisodamine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Anisodamine.	Investigational
Anisotropine Methylbromide	The serum concentration of Chlorothiazide can be increased when it is combined with Anisotropine Methylbromide.	Approved
Antipyrine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.	Approved
Apocynin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetovanillone.	Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apraclonidine.	Approved
Apremilast	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apremilast.	Approved, Investigational
Arbutamine	Arbutamine may increase the hypokalemic activities of Chlorothiazide.	Approved
Arformoterol	Arformoterol may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arotinolol.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arsenic trioxide.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Chlorothiazide.	Approved
Atracurium besylate	The serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.	Approved
Atropine	The serum concentration of Chlorothiazide can be increased when it is combined with Atropine.	Approved, Vet Approved
Azapropazone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.	Withdrawn
Azelastine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Chlorothiazide.	Investigational
Balsalazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.	Approved, Investigational
Bambuterol	Bambuterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Barbexaclone	Barbexaclone may increase the orthostatic hypotensive activities of Chlorothiazide.	Experimental
Barbital	Barbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Barnidipine.	Approved
Beclomethasone dipropionate	Beclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Benactyzine	The serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine.	Withdrawn
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Chlorothiazide.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Chlorothiazide.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Benoxaprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen.	Withdrawn
Benzatropine	The serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine.	Approved
Bepridil	Chlorothiazide may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betamethasone	Betamethasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorothiazide.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Chlorothiazide.	Approved
Betulinic Acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Betulinic Acid.	Investigational
Bezitramide	The risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide.	Experimental, Illicit, Withdrawn
Bimatoprost	Chlorothiazide may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Biperiden	The serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.	Approved
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Chlorothiazide.	Approved
Bortezomib	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bortezomib.	Approved, Investigational
Bosentan	Bosentan may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Bretylium	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bretylium.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Chlorothiazide.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Chlorothiazide.	Approved
Bromfenac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.	Approved
Bromocriptine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bromocriptine.	Approved, Investigational
Bucillamine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bucillamine.	Investigational
Budesonide	Budesonide may increase the hypokalemic activities of Chlorothiazide.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Chlorothiazide.	Withdrawn
Bumetanide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Chlorothiazide may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.	Approved, Illicit, Investigational, Vet Approved
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.	Approved, Illicit, Vet Approved
Calcidiol	Chlorothiazide may increase the hypercalcemic activities of Calcidiol.	Approved, Nutraceutical
Calcipotriol	Chlorothiazide may increase the hypercalcemic activities of Calcipotriol.	Approved
Calcitriol	Chlorothiazide may increase the hypercalcemic activities of Calcitriol.	Approved, Nutraceutical
Calcium	Chlorothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.	Nutraceutical
Calcium Acetate	Chlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.	Approved
Calcium Carbonate	Chlorothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.	Approved
Calcium Chloride	Chlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.	Approved
Calcium Citrate	Chlorothiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.	Approved
Calcium glubionate	Chlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.	Approved
Calcium Gluceptate	Chlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.	Approved
Calcium gluconate	Chlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.	Approved, Vet Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Chlorothiazide.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Chlorothiazide.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Captopril.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbetocin.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorothiazide.	Illicit, Vet Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Carprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Chlorothiazide.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carvedilol.	Approved, Investigational
Castanospermine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine.	Experimental
Celecoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.	Approved, Investigational
Celiprolol	Celiprolol may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Chloroquine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.	Approved, Vet Approved
Chlorphenoxamine	The serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine.	Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.	Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorothiazide.	Approved
Cholecalciferol	Chlorothiazide may increase the hypercalcemic activities of Cholecalciferol.	Approved, Nutraceutical
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trisalicylate-choline.	Approved
Ciclesonide	Ciclesonide may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.	Experimental
Cilazapril	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilnidipine.	Approved
Citalopram	Citalopram may increase the hyponatremic activities of Chlorothiazide.	Approved
Clenbuterol	Clenbuterol may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Clevidipine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.	Approved
Clobetasol	Clobetasol may increase the hypokalemic activities of Chlorothiazide.	Investigational
Clobetasol propionate	Clobetasol propionate may increase the hypokalemic activities of Chlorothiazide.	Approved
Clocortolone	Clocortolone may increase the hypokalemic activities of Chlorothiazide.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clofarabine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Chlorothiazide.	Approved
Clonixin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin.	Approved
Clozapine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clozapine.	Approved
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide.	Approved, Illicit
Colesevelam	Colesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Conivaptan.	Approved, Investigational
Cortisone acetate	Cortisone acetate may increase the hypokalemic activities of Chlorothiazide.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Chlorothiazide.	Approved
Curcumin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Curcumin.	Investigational
Cyclopentolate	The serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.	Approved, Investigational
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Chlorothiazide.	Approved
D-Limonene	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with D-Limonene.	Investigational
Dapagliflozin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.	Approved
Dapoxetine	Dapoxetine may increase the hyponatremic activities of Chlorothiazide.	Investigational
Darifenacin	The serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.	Approved, Investigational
Debrisoquin	Chlorothiazide may increase the hypotensive activities of Debrisoquin.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Chlorothiazide.	Investigational
Deserpidine	Chlorothiazide may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Desflurane.	Approved
Deslanoside	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.	Approved
Desloratadine	The serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.	Approved, Investigational
Desoximetasone	Desoximetasone may increase the hypokalemic activities of Chlorothiazide.	Approved
Desoxycorticosterone acetate	Desoxycorticosterone acetate may increase the hypokalemic activities of Chlorothiazide.	Approved
Desoxycorticosterone Pivalate	Desoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorothiazide.	Experimental, Vet Approved
Desvenlafaxine	Desvenlafaxine may increase the hyponatremic activities of Chlorothiazide.	Approved
Dexamethasone	Dexamethasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	Dexamethasone isonicotinate may increase the hypokalemic activities of Chlorothiazide.	Vet Approved
Dexetimide	The serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide.	Withdrawn
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorothiazide.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Chlorothiazide.	Approved
Diazoxide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diazoxide.	Approved
Diclofenac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide.	Approved
Dicyclomine	The serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.	Approved
Diflorasone	Diflorasone may increase the hypokalemic activities of Chlorothiazide.	Approved
Diflunisal	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.	Approved
Difluocortolone	Difluocortolone may increase the hypokalemic activities of Chlorothiazide.	Approved
Difluprednate	Difluprednate may increase the hypokalemic activities of Chlorothiazide.	Approved
Digitoxin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.	Approved
Digoxin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.	Approved
Dihydralazine	Chlorothiazide may increase the hypotensive activities of Dihydralazine.	Investigational
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.	Experimental, Illicit
Dihydrotachysterol	Chlorothiazide may increase the hypercalcemic activities of Dihydrotachysterol.	Approved
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Chlorothiazide.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.	Approved, Illicit
Dipivefrin	Dipivefrin may increase the hypokalemic activities of Chlorothiazide.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.	Approved
Dobutamine	Dobutamine may increase the hypokalemic activities of Chlorothiazide.	Approved
Dofetilide	Chlorothiazide may increase the QTc-prolonging activities of Dofetilide.	Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Chlorothiazide.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.	Approved
Doxercalciferol	Chlorothiazide may increase the hypercalcemic activities of Doxercalciferol.	Approved
DPDPE	The risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide.	Investigational
Droxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam.	Approved
Droxidopa	Droxidopa may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.	Approved
Duloxetine	Chlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Duvelisib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib.	Investigational
E-6201	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with E6201.	Investigational
Ebselen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ebselen.	Investigational
Efonidipine	Chlorothiazide may increase the hypotensive activities of Efonidipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Chlorothiazide.	Approved, Vet Approved
Enalaprilat	Chlorothiazide may increase the hypotensive activities of Enalaprilat.	Approved
Ephedra	Ephedra may increase the hypokalemic activities of Chlorothiazide.	Approved, Nutraceutical, Withdrawn
Epinephrine	Epinephrine may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Epirizole	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide.	Approved
Epoprostenol	Chlorothiazide may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorothiazide.	Approved
Equilenin	Equilenin may increase the hypokalemic activities of Chlorothiazide.	Experimental
Equilin	Equilin may increase the hypokalemic activities of Chlorothiazide.	Approved
Ergocalciferol	Chlorothiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved, Nutraceutical
Escitalopram	Escitalopram may increase the hyponatremic activities of Chlorothiazide.	Approved, Investigational
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.	Approved
Estrone	Estrone may increase the hypokalemic activities of Chlorothiazide.	Approved
Estrone sulfate	Estrone sulfate may increase the hypokalemic activities of Chlorothiazide.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.	Approved
Etanercept	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.	Approved, Investigational
Ethanol	Ethanol may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved
Ethopropazine	The serum concentration of Chlorothiazide can be increased when it is combined with Ethopropazine.	Approved
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.	Approved, Illicit
Etodolac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate.	Approved
Etoperidone	Etoperidone may increase the hyponatremic activities of Chlorothiazide.	Approved
Etoricoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide.	Illicit, Vet Approved
Evening primrose oil	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Evening primrose oil.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
exisulind	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with exisulind.	Investigational
Felodipine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Felodipine.	Approved, Investigational
Fenbufen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen.	Approved
Fenoldopam	Fenoldopam may increase the hypotensive activities of Chlorothiazide.	Approved
Fenoprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.	Approved
Fenoterol	Fenoterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Fimasartan.	Approved
Floctafenine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Floctafenine.	Approved, Withdrawn
fluasterone	fluasterone may increase the hypokalemic activities of Chlorothiazide.	Investigational
Fludrocortisone	Fludrocortisone may increase the hypokalemic activities of Chlorothiazide.	Approved
Flumethasone	Flumethasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Flunisolide	Flunisolide may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Flunixin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunixin.	Vet Approved
Fluocinolone Acetonide	Fluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational, Vet Approved
Fluocinonide	Fluocinonide may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Fluocortolone	Fluocortolone may increase the hypokalemic activities of Chlorothiazide.	Approved, Withdrawn
Fluorometholone	Fluorometholone may increase the hypokalemic activities of Chlorothiazide.	Approved
Fluoxetine	Fluoxetine may increase the hyponatremic activities of Chlorothiazide.	Approved, Vet Approved
Fluprednidene	Fluprednidene may increase the hypokalemic activities of Chlorothiazide.	Approved, Withdrawn
Fluprednisolone	Fluprednisolone may increase the hypokalemic activities of Chlorothiazide.	Approved
Flurandrenolide	Flurandrenolide may increase the hypokalemic activities of Chlorothiazide.	Approved
Flurbiprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.	Approved, Investigational
Fluticasone furoate	Fluticasone furoate may increase the hypokalemic activities of Chlorothiazide.	Approved
Fluticasone propionate	Fluticasone Propionate may increase the hypokalemic activities of Chlorothiazide.	Approved
Fluvoxamine	Fluvoxamine may increase the hyponatremic activities of Chlorothiazide.	Approved, Investigational
Formestane	Formestane may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational, Withdrawn
Formoterol	Formoterol may increase the hypokalemic activities of Chlorothiazide.	Approved, Investigational
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorothiazide.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.	Approved, Vet Approved
Gallamine Triethiodide	The serum concentration of Chlorothiazide can be increased when it is combined with Gallamine Triethiodide.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorothiazide.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.	Approved
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide.	Approved
Glycopyrronium	The serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium.	Approved, Investigational, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Chlorothiazide.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Chlorothiazide.	Approved
Guanethidine	Chlorothiazide may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Guanfacine.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorothiazide.	Investigational
Halothane	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Halothane.	Approved, Vet Approved
HE3286	HE3286 may increase the hypokalemic activities of Chlorothiazide.	Investigational
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Chlorothiazide.	Approved, Illicit
Hexamethonium	The serum concentration of Chlorothiazide can be increased when it is combined with Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved
Higenamine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Higenamine.	Investigational
Homatropine	The serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Chlorothiazide.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.	Approved, Illicit
Hydrocortisone	Hydrocortisone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Chlorothiazide.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.	Approved, Illicit
Hyoscyamine	The serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.	Approved
Ibuprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.	Approved
Ibuproxam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuproxam.	Withdrawn
Icatibant	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Imidapril.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Imipramine.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Indalpine	Indalpine may increase the hyponatremic activities of Chlorothiazide.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Chlorothiazide.	Approved
Indenolol	Chlorothiazide may increase the hypotensive activities of Indenolol.	Withdrawn
Indomethacin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.	Approved, Investigational
Indoprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen.	Withdrawn
Indoramin	Chlorothiazide may increase the hypotensive activities of Indoramin.	Withdrawn
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorothiazide.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorothiazide.	Approved
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.	Approved
Ipratropium bromide	The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.	Approved
Iproclozide	Iproclozide may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Irbesartan.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Chlorothiazide.	Approved
Isoetarine	Isoetarine may increase the hypokalemic activities of Chlorothiazide.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoflurane.	Approved, Vet Approved
Isoprenaline	Isoprenaline may increase the hypokalemic activities of Chlorothiazide.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.	Approved
Isoxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Chlorothiazide.	Approved
Istaroxime	Istaroxime may increase the hypokalemic activities of Chlorothiazide.	Investigational
Ivabradine	Chlorothiazide may increase the arrhythmogenic activities of Ivabradine.	Approved
Kebuzone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone.	Experimental
Ketanserin	Chlorothiazide may increase the hypotensive activities of Ketanserin.	Investigational
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.	Approved
Ketoprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Ketorolac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.	Approved
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Chlorothiazide.	Approved
Lacidipine	Chlorothiazide may increase the hypotensive activities of Lacidipine.	Approved
Latanoprost	Latanoprost may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Leflunomide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Leflunomide.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobupivacaine.	Approved
Levodopa	Chlorothiazide may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.	Approved
Levomilnacipran	Levomilnacipran may increase the hyponatremic activities of Chlorothiazide.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levosimendan.	Approved, Investigational
Licorice	Licorice may increase the hypokalemic activities of Chlorothiazide.	Approved
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorothiazide.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Chlorothiazide.	Approved, Investigational
Lisofylline	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline.	Investigational
Lithium	Chlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorothiazide.	Illicit
Lofexidine	Chlorothiazide may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lornoxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Chlorothiazide.	Approved
Loxoprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen.	Approved
Lumiracoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib.	Approved, Investigational
Macitentan	Chlorothiazide may increase the hypotensive activities of Macitentan.	Approved
Magnesium salicylate	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.	Approved
Manidipine	Chlorothiazide may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.	Approved, Investigational
Masoprocol	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.	Approved
ME-609	ME-609 may increase the hypokalemic activities of Chlorothiazide.	Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.	Approved
Meclofenamic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Medrysone	Medrysone may increase the hypokalemic activities of Chlorothiazide.	Approved
Mefenamic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.	Approved
Melengestrol	Melengestrol may increase the hypokalemic activities of Chlorothiazide.	Vet Approved
Meloxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.	Approved, Vet Approved
Mesalazine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.	Approved
Metamizole	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.	Withdrawn
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorothiazide.	Approved, Illicit
Methantheline	The serum concentration of Chlorothiazide can be increased when it is combined with Methantheline.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorothiazide.	Approved
Methohexital	Methohexital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Chlorothiazide.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Chlorothiazide.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved
Methylprednisolone	Methylprednisolone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Metipranolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metipranolol.	Approved
Metixene	The serum concentration of Chlorothiazide can be increased when it is combined with Metixene.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide.	Approved
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorothiazide.	Approved, Investigational
Metyrosine	Chlorothiazide may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Chlorothiazide may increase the hypotensive activities of Mibefradil.	Withdrawn
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorothiazide.	Approved
Milnacipran	Milnacipran may increase the hyponatremic activities of Chlorothiazide.	Approved
Minaprine	Minaprine may increase the hypotensive activities of Chlorothiazide.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorothiazide.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Mizoribine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Chlorothiazide.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Chlorothiazide.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Chlorothiazide.	Approved
Mometasone	Mometasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.	Approved, Investigational
Moxonidine	Chlorothiazide may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.	Approved, Investigational
Mycophenolic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nabilone.	Approved, Investigational
Nabumetone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.	Approved
Nadolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nadolol.	Approved
Nafamostat	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.	Approved, Investigational
Naftifine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine.	Approved
Naftopidil	Chlorothiazide may increase the hypotensive activities of Naftopidil.	Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.	Approved
Naproxen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.	Approved, Vet Approved
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
NCX 1022	NCX 1022 may increase the hypokalemic activities of Chlorothiazide.	Investigational
Nebivolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nebivolol.	Approved, Investigational
Nefazodone	Nefazodone may increase the hyponatremic activities of Chlorothiazide.	Approved, Withdrawn
Nepafenac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nesiritide.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Chlorothiazide.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Chlorothiazide.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.	Approved
Niflumic Acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.	Approved
Niguldipine	Chlorothiazide may increase the hypotensive activities of Niguldipine.	Experimental
Nilvadipine	Chlorothiazide may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorothiazide.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Chlorothiazide.	Approved
Nitrendipine	Chlorothiazide may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nitric Oxide.	Approved
Nitroaspirin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nitroaspirin.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorothiazide.	Approved
Norepinephrine	Norepinephrine may increase the hypokalemic activities of Chlorothiazide.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Chlorothiazide.	Approved, Illicit
Obinutuzumab	Chlorothiazide may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Oleandrin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Anvirzel.	Experimental
Oleoyl-estrone	Oleoyl estrone may increase the hypokalemic activities of Chlorothiazide.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorothiazide.	Approved, Investigational
Olodaterol	Olodaterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Olopatadine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.	Approved
Olsalazine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.	Approved
Omapatrilat	Chlorothiazide may increase the hypotensive activities of Omapatrilat.	Investigational
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Chlorothiazide.	Approved, Illicit
Orciprenaline	Orciprenaline may increase the hypokalemic activities of Chlorothiazide.	Approved
Orgotein	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Orgotein.	Vet Approved
Orphenadrine	The serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.	Approved
Ouabain	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.	Approved
Oxaprozin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.	Approved
Oxcarbazepine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oxcarbazepine.	Approved
Oxprenolol	Chlorothiazide may increase the hypotensive activities of Oxprenolol.	Approved
Oxybutynin	The serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.	Approved, Investigational, Vet Approved
Oxyphenbutazone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.	Withdrawn
Oxyphenonium	The serum concentration of Chlorothiazide can be increased when it is combined with Oxyphenonium.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Paclitaxel.	Approved, Vet Approved
Pancuronium	The serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.	Approved
Paramethasone	Paramethasone may increase the hypokalemic activities of Chlorothiazide.	Approved
Parecoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Chlorothiazide.	Approved
Paricalcitol	Chlorothiazide may increase the hypercalcemic activities of Paricalcitol.	Approved, Investigational
Paroxetine	Paroxetine may increase the hyponatremic activities of Chlorothiazide.	Approved, Investigational
Penbutolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Penbutolol.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.	Approved, Vet Approved
Pentobarbital	Pentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Pentolinium	The serum concentration of Chlorothiazide can be increased when it is combined with Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Chlorothiazide.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Chlorothiazide.	Approved
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorothiazide.	Approved, Withdrawn
Pheniprazine	Pheniprazine may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Phenobarbital	Phenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved
Phenoxybenzamine	Chlorothiazide may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Chlorothiazide.	Approved
Phenylbutazone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.	Approved, Vet Approved
Phenylpropanolamine	Phenylpropanolamine may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved, Withdrawn
Pimecrolimus	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.	Approved, Investigational
Pinacidil	Chlorothiazide may increase the hypotensive activities of Pinacidil.	Withdrawn
Pindolol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pindolol.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pipamperone.	Approved
Pipecuronium	The serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.	Approved
Pirbuterol	Pirbuterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Pirenzepine	The serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.	Approved
Pirfenidone	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.	Investigational
Piritramide	The risk or severity of adverse effects can be increased when Piritramide is combined with Chlorothiazide.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Chlorothiazide.	Approved
Piroxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Polythiazide	Chlorothiazide may increase the hypotensive activities of Polythiazide.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pramipexole.	Approved, Investigational
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Prasterone	Prasterone may increase the hypokalemic activities of Chlorothiazide.	Approved, Nutraceutical
Prasterone sulfate	dehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorothiazide.	Investigational
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Chlorothiazide.	Approved
Prednicarbate	Prednicarbate may increase the hypokalemic activities of Chlorothiazide.	Approved
Prednisolone	Prednisolone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Prednisone	Prednisone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Pregnenolone	Pregnenolone may increase the hypokalemic activities of Chlorothiazide.	Experimental
Primidone	Primidone may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Procaterol	Procaterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Procyclidine	The serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.	Approved
Propacetamol	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol.	Approved
Propantheline	The serum concentration of Chlorothiazide can be increased when it is combined with Propantheline.	Approved
Propiverine	The serum concentration of Chlorothiazide can be increased when it is combined with Propiverine.	Investigational
Propofol	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Chlorothiazide.	Approved, Investigational
PTC299	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299.	Investigational
Quetiapine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quinapril.	Approved, Investigational
Quinidine	The serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.	Approved
Quinine	Quinine may increase the hypotensive activities of Chlorothiazide.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Chlorothiazide.	Approved
Rasagiline	Rasagiline may increase the hypotensive activities of Chlorothiazide.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Chlorothiazide.	Approved
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Rescinnamine	Chlorothiazide may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Chlorothiazide.	Approved
Resveratrol	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.	Experimental, Investigational
Rilmenidine	Chlorothiazide may increase the hypotensive activities of Rilmenidine.	Investigational
Rimexolone	Rimexolone may increase the hypokalemic activities of Chlorothiazide.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Riociguat.	Approved
Risperidone	Chlorothiazide may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritodrine	Ritodrine may increase the hypokalemic activities of Chlorothiazide.	Approved
Rituximab	Chlorothiazide may increase the hypotensive activities of Rituximab.	Approved
Rofecoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Rofecoxib.	Investigational, Withdrawn
Ropinirole	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropivacaine.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Rotigotine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Chlorothiazide.	Withdrawn
Salbutamol	Salbutamol may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Salicylamide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.	Approved
Salicylic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid.	Approved, Vet Approved
Salmeterol	Salmeterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Salsalate	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.	Approved
Saprisartan	Chlorothiazide may increase the hypotensive activities of Saprisartan.	Experimental
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorothiazide.	Approved
Scopolamine	The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.	Approved
Scopolamine butylbromide	The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide.	Approved, Vet Approved
Secobarbital	Secobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational, Vet Approved
Selexipag	Chlorothiazide may increase the hypotensive activities of Selexipag.	Approved
Seratrodast	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.	Approved
Sertraline	Sertraline may increase the hyponatremic activities of Chlorothiazide.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Chlorothiazide.	Approved, Investigational
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Sitaxentan	Chlorothiazide may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium Nitrite	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sodium Nitrite.	Approved
Solifenacin	The serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin.	Approved
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.	Approved
Spirapril	Chlorothiazide may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.	Approved
SRT501	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501.	Investigational
Streptokinase	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.	Approved, Investigational
Sulfasalazine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.	Approved
Sulindac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.	Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.	Approved
Suprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.	Approved, Withdrawn
Tadalafil	Tadalafil may increase the antihypertensive activities of Chlorothiazide.	Approved, Investigational
Tamsulosin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tamsulosin.	Approved, Investigational
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Telmisartan.	Approved, Investigational
Temocapril	Chlorothiazide may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Tenoxicam	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.	Approved
Tepoxalin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tepoxalin.	Vet Approved
Terazosin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.	Approved
Terbutaline	Terbutaline may increase the hypokalemic activities of Chlorothiazide.	Approved
Teriflunomide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.	Approved
Terlipressin	Chlorothiazide may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	Thiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Thiopental	Thiopental may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thioridazine.	Withdrawn
Tiaprofenic acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.	Approved
Tibolone	Chlorothiazide may increase the hypotensive activities of Tibolone.	Approved
Ticrynafen	Chlorothiazide may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Chlorothiazide.	Approved
Tinoridine	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tinoridine.	Investigational
Tiotropium	The serum concentration of Chlorothiazide can be increased when it is combined with Tiotropium.	Approved
Tixocortol	Tixocortol may increase the hypokalemic activities of Chlorothiazide.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.	Approved
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.	Approved
Tolmetin	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Chlorothiazide.	Approved
Tolterodine	The serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine.	Approved, Investigational
Topiramate	Chlorothiazide may increase the hypokalemic activities of Topiramate.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Chlorothiazide.	Approved
Toremifene	Chlorothiazide may increase the hypercalcemic activities of Toremifene.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorothiazide.	Approved
Tranilast	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Chlorothiazide.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Chlorothiazide.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Chlorothiazide.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamcinolone	Triamcinolone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.	Approved
Trichlormethiazide	Chlorothiazide may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trihexyphenidyl	The serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl.	Approved
Trimazosin	Chlorothiazide may increase the hypotensive activities of Trimazosin.	Experimental
Trimethaphan	The serum concentration of Chlorothiazide can be increased when it is combined with Trimethaphan.	Approved
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorothiazide.	Withdrawn
Tropicamide	The serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide.	Approved
Trospium	The serum concentration of Chlorothiazide can be increased when it is combined with Trospium.	Approved
Tubocurarine	The serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Chlorothiazide.	Approved, Investigational
Umeclidinium	The serum concentration of Chlorothiazide can be increased when it is combined with Umeclidinium.	Approved
Unoprostone	Chlorothiazide may increase the hypotensive activities of Unoprostone.	Approved
Valdecoxib	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.	Investigational, Withdrawn
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Chlorothiazide.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Chlorothiazide.	Approved
Vecuronium	The serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.	Approved
Venlafaxine	Venlafaxine may increase the hyponatremic activities of Chlorothiazide.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.	Approved
Vilanterol	Vilanterol may increase the hypokalemic activities of Chlorothiazide.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Vinpocetine	Chlorothiazide may increase the hypotensive activities of Vinpocetine.	Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorothiazide.	Approved, Investigational
Xylometazoline	Chlorothiazide may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Chlorothiazide.	Approved, Vet Approved
Zaltoprofen	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.	Approved
Zileuton	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zileuton.	Approved, Investigational, Withdrawn
Zimelidine	Zimelidine may increase the hyponatremic activities of Chlorothiazide.	Withdrawn
Zomepirac	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Eugene S. Barabas, "Water soluble complex of a poly (vinyl lactam) and chlorothiazide and process for producing same." U.S. Patent US4713238, issued December, 1985.

US4713238

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15018
KEGG Drug	D00519
KEGG Compound	C07461
PubChem Compound	2720
PubChem Substance	46507032
ChemSpider	2619
BindingDB	39351
ChEBI	3640
ChEMBL	CHEMBL842
Therapeutic Targets Database	DAP000605
PharmGKB	PA448953
Drug Product Database	10203
RxList	http://www.rxlist.com/cgi/generic2/chloroth.htm
Drugs.com	http://www.drugs.com/cdi/chlorothiazide.html
Wikipedia	Chlorothiazide

ATC Codes

C03AA04 — Chlorothiazide

C03AB04 — Chlorothiazide and potassium

G01AE10 — Combinations of sulfonamides

C03AH01 — Chlorothiazide, combinations

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (72.7 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Completed	Prevention	Cardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases	1
4	Enrolling by Invitation	Treatment	Heart Failure, Unspecified	1
Not Available	Completed	Screening	Diabetes Insipidus, Nephrogenic	1
Not Available	Recruiting	Diagnostic	Heart Failure, Unspecified	1

Pharmacoeconomics

Manufacturers

Salix pharmaceuticals inc
Abc holding corp
Lederle laboratories div american cyanamid co
Mylan pharmaceuticals inc
Sandoz inc
Watson laboratories inc
West ward pharmaceutical corp
Lundbeck inc
App pharmaceuticals llc

Packagers

Dosage forms

Form	Route	Strength
Tablet	Oral	250 mg/1
Tablet	Oral	500 mg/1
Injection	Intravenous	500 mg/1
Injection, powder, lyophilized, for solution	Intravenous	500 mg/18mL
Suspension	Oral	250 mg/5mL
Injection	Intravenous	.5 mg/18mL
Tablet	Oral

Prices

Unit description	Cost	Unit
Diuril sodium 500 mg vial	519.62USD	vial
Chlorothiazide sod 500 mg vial	357.24USD	vial
Microzide 12.5 mg capsule	0.95USD	capsule
Aldoclor 250-250 mg tablet	0.67USD	tablet
Chlorothiazide 500 mg tablet	0.36USD	tablet
Chlorothiazide 250 mg tablet	0.28USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	342.5-343	Novello, F.C.; US. Patent 2,809,194; October 8,1957; assigned to Merck & Co.,Inc. Hinkley, D.F.; US. Patent 2,937,169; May 17,1960; assigned to Merck & Co., Inc.
water solubility	266 mg/L (at 30 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	-0.24	HANSCH,C ET AL. (1995)
logS	-3.05	ADME Research, USCD
Caco2 permeability	-6.72	ADME Research, USCD
pKa	6.85	MERCK INDEX (1996)

Predicted Properties

Property	Value	Source
Water Solubility	0.398 mg/mL	ALOGPS
logP	0.41	ALOGPS
logP	-0.44	ChemAxon
logS	-2.9	ALOGPS
pKa (Strongest Acidic)	9.1	ChemAxon
pKa (Strongest Basic)	1.15	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	118.69 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	62.51 m³·mol^-1	ChemAxon
Polarizability	24.55 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9119
Blood Brain Barrier	-	0.9506
Caco-2 permeable	-	0.7368
P-glycoprotein substrate	Non-substrate	0.706
P-glycoprotein inhibitor I	Non-inhibitor	0.8482
P-glycoprotein inhibitor II	Non-inhibitor	0.8381
Renal organic cation transporter	Non-inhibitor	0.8177
CYP450 2C9 substrate	Non-substrate	0.755
CYP450 2D6 substrate	Non-substrate	0.8379
CYP450 3A4 substrate	Non-substrate	0.6308
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9382
CYP450 3A4 inhibitor	Non-inhibitor	0.8901
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8658
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.7792
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	1.5023 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9654
hERG inhibition (predictor II)	Non-inhibitor	0.9352

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (10.1 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0006-0090000000-e74dd6446e0284a7f0aa	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0006-0090000000-baf93e639a13c39dc1d6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-01ox-0090000000-473477518be3f6c8ddcd	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0290000000-0e599c26917ade291ca0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0890000000-ad270ef1247ce9a114ad	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-0920000000-3c4bb920bb8316022718	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-2900000000-eca13dbca70054de3470	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-02vr-9700000000-9261e1bf4e212aee7d84	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0i09-9100000000-491baf01fc6ef9ca39e1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0002-0090000000-388cb4ff11dc0a41ad99	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-002b-0090000000-5645eee512f78cd689a7	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0udi-0390000000-a39ffe78224ed4cacc13	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0pbl-0920000000-eb979e3c4ecd1f12fb71	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-059f-2900000000-4c2eb27958fba0102431	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-05tk-5900000000-b42b446bc2b9f6216af1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-00kk-9400000000-b4b975e3c1fabe09f4a7	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-9100000000-f8f80586b12a43c2a667	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-9000000000-9d41a0f061f998097c17	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Thiadiazines

Direct Parent

1,2,4-benzothiadiazine-1,1-dioxides

Alternative Parents

Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Formamidines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides

Substituents

1,2,4-benzothiadiazine-1,1-dioxide / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound / Propargyl-type 1,3-dipolar organic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

benzothiadiazine (CHEBI:3640 )

Targets

Details

1. Solute carrier family 12 member 3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Transporter activity
Specific Function:: Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:: SLC12A3
Uniprot ID:: P55017
Uniprot Name:: Solute carrier family 12 member 3
Molecular Weight:: 113138.04 Da

References

Thakker RV: Molecular pathology of renal chloride channels in Dent's disease and Bartter's syndrome. Exp Nephrol. 2000 Nov-Dec;8(6):351-60. [PubMed:11014932 ]
Schmidt H, Kabesch M, Schwarz HP, Kiess W: Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res. 2001 Jun;33(6):354-7. [PubMed:11456284 ]
Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):680-4. Epub 2003 Jan 6. [PubMed:12515852 ]
Maki N, Komatsuda A, Wakui H, Ohtani H, Kigawa A, Aiba N, Hamai K, Motegi M, Yamaguchi A, Imai H, Sawada K: Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome. Nephrol Dial Transplant. 2004 Jul;19(7):1761-6. Epub 2004 Apr 6. [PubMed:15069170 ]
Reinalter SC, Jeck N, Peters M, Seyberth HW: Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand. 2004 Aug;181(4):513-21. [PubMed:15283765 ]

Details

2. Carbonic anhydrase 1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:: CA1
Uniprot ID:: P00915
Uniprot Name:: Carbonic anhydrase 1
Molecular Weight:: 28870.0 Da

References

Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]

Details

3. Carbonic anhydrase 2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:: CA2
Uniprot ID:: P00918
Uniprot Name:: Carbonic anhydrase 2
Molecular Weight:: 29245.895 Da

References

Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8. [PubMed:14656370 ]
Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]
Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney. Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8. [PubMed:12388412 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

4. Carbonic anhydrase 4

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:: CA4
Uniprot ID:: P22748
Uniprot Name:: Carbonic anhydrase 4
Molecular Weight:: 35032.075 Da

References

Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]

Transporters

Details

1. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:: SLC22A6
Uniprot ID:: Q4U2R8
Uniprot Name:: Solute carrier family 22 member 6
Molecular Weight:: 61815.78 Da

References

Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:33

Structure for DB00880 (Chlorothiazide)

Targets

References

References

References

References

Transporters

References